• In August 2026, Harrow, Inc. reported second-quarter revenue of US$70.66 million versus US$63.74 million a year earlier, swung to a net loss of US$17.27 million, and reiterated its 2026 revenue guidance of US$350 million to US$365 million.
• Just days earlier, Harrow agreed to acquire TYRVAYA nasal spray for up to US$100 million, aiming to broaden its dry eye disease franchise with a drop-free treatment that complements its existing VEVYE offering.
• Next, we’ll examine how reaffirmed 2026 revenue guidance alongside the TYRVAYA acquisition could reshape Harrow’s previously outlined investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Harrow Investment Narrative Recap

To own Harrow, you need to believe its focused ophthalmic portfolio can translate strong revenue guidance into sustainable profitability despite ongoing losses. The reaffirmed 2026 revenue outlook alongside a wider dry eye offering makes the near term execution catalyst more visible, but also sharpens the key risk: Harrow is still loss making, and layering acquisitions and higher operating costs on top of that profile could prolong the path to consistent earnings.

The TYRVAYA acquisition announcement feels most relevant here. It deepens Harrow’s concentration in dry eye disease alongside VEVYE, potentially enhancing the appeal of its portfolio ahead of upcoming commercial milestones for other ophthalmic launches. At the same time, adding up to US$100 million of deal commitments and integration work into a business that just swung from profit to loss reinforces the concern that execution missteps across a tightly focused product set could weigh on both margins and future guidance.

Yet behind the stronger dry eye story, investors should also be aware of how concentrated Harrow remains in ophthalmic products and what that could mean if...

Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 73% upside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts already worried about Harrow’s dependence on new launches, even while forecasting revenue to reach about US$707 million and earnings near US$140 million by 2029, so you should expect views on the TYRVAYA deal and the reiterated 2026 guidance to differ and potentially shift as updated scenarios emerge.

Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.